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Dear Editor,
We have read with a great interest the paper by Kavak and Özdemir [1] , recently published online in the Journal of Surgery and Medicine. In a total of 61 patients with lung cancer, with no brain metastasis, no history of radiation, no history of renal failure they reported an increase in signal intensity (SI) in unenhanced T1-weighted MRI in the brain following repeated administrations of gadoterate meglumine at the standard dose of 0.1 mmol/kg of body weight. The increase in SI was reported in several brain areas: dentate nucleus (DN), pons (P), globus pallidus (GP) and thalamus (T). As stated by the authors, the mean SI in DN, P, GP and T were divided by the mean values obtained from the cerebrospinal fluid (CSF) to standardize the SI measurements and an increase in the four respective ratios was reported as well. These results are conflicting with all the published data from well controlled studies showing no increase in signal intensity with macrocyclic agents [2] . Furthermore, several methodological aspects of that study do not match with the recently published recommendations [2] .
First, although it is stated that a minimum of 3 injections and a maximum of 5 injections were given, the cumulative dose (mean and range) of gadoterate meglumine is not specified.
Second, the DN-to-pons ratio has not been assessed although this ratio has been used in most of the reported studies. The author did not justify why they did not choose pons as the reference region. Considering the pharmacokinetic profile of macrocyclic agents in the CSF compartment [3, 4, 5] , CSF is not an appropriate reference region to standardize SI values from other cerebral regions. The reported ratio increases (DN/CSF, P/CSF, GP/CSF, T/CSF) could be due to specific variations from CSF signal intensity. In addition, since the ratio of the means is different from the mean of the individual ratios, the ratios should have been calculated for each individual instead of dividing, for each specific brain area, the mean SI by the mean SI in CSF. Last, but not least, the increase in SI value in pons, which is commonly recognized as reference region, strongly suggests an experimental bias favorizing a global increase in SI values in multiple brain regions beyond the DN and GP known as the specific brain regions for gadolinium deposition.
Third, there was no control group without gadolinium-based agents injection. In absence of control group, the impact of CSF SI on SI ratio values cannot be evaluated and increases in SI values cannot be confirmed.
Fourth, DN, P, GP, and T SI changes were reported between first and last unenhanced MRI. Additional time points, which were available in this study, since correlation between ratio values and number of MRI was tested, should have been shown for a robust conclusion.
Fifth, it is stated that "The number of examinations had a moderately positive correlation with DN/CSF ratio and a strongly positive correlation with the P/CSF ratio" which is not consistent with the correlation coefficient values reported in the Table 3 , e.g. 0.490 and 0.577, respectively. Both values represent only moderate correlation. In the absence of individual data (which could have been reported in a graph) the conclusion is misleading.
Finally, the Stojanov [6] and Rossi-Espagnet [7] studies were reported without mentioning the respective associated controversies on these publications [8, 9] .
Taking into consideration these significant limitations, the authors might mitigate their conclusion emphasizing that further studieswith more robust approach -should be investigated to confirm these unexpected results.
